Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer

  Illumina Names Dr. Richard Klausner as Senior Vice President and Chief
  Medical Officer

Business Wire

SAN DIEGO -- September 23, 2013

Illumina (NASDAQ:ILMN) today announced it has appointed Dr. Richard Klausner
as Senior Vice President and Chief Medical Officer. Dr. Klausner will report
to President and Chief Executive Officer Jay Flatley and will lead Illumina’s
strategies for advancing genomics into clinical medicine and public health. He
will also become part of Illumina’s executive management team, which is
responsible for directing all aspects of company strategy, planning and
operations.

“Rick’s expertise in molecular biology, his experience in life sciences, and
his roles in global health policy make him uniquely suited to mobilize
constituents around the use of genomics within medical practice,” said Jay
Flatley. “We are very excited about his vision and passion for ushering in a
new era of precision medicine and his ability to work with clinicians,
industry, government, and academia to help bring this vision to fruition.”

Prior to joining Illumina, Dr. Klausner was managing partner of the venture
capital firm, The Column Group. Previously, he held roles as Executive
Director for Global Health at the Bill and Melinda Gates Foundation and as the
eleventh director of the National Cancer Institute between 1995 and 2001. He
has served as chief of the cell biology and metabolism branch of the National
Institute of Child Health and Human Development, as well as a past president
of the American Society of Clinical Investigation. He also has been Chairman
of the National Science Education Standards Projects of the National Academy
of Sciences.

Dr. Klausner is well known for his work in cell and molecular biology, and is
the author of more than 300 scientific articles and several books, in addition
to receiving numerous awards and honors. He has served as an Advisor to the
Presidents of the Academies for counter-terrorism, as a Liaison to the White
House Office of Science & Technology Policy, and as a Chief Strategy Advisor
for USAID. He currently chairs the International Advisory Board for Samsung,
is the Chairman of Audax Health, and previously chaired the Strategic
Oversight Council of Sanofi. He is a member of the National Academy of
Sciences, the Institute of Medicine, and the American Academy of Arts and
Sciences. Dr. Klausner holds an M.D. from Duke Medical School.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.